Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 μg/L: Are they useful tools for early detection and screening of prostate cancer?

International Journal of Cancer

Volumn 93, Issue 5, 2001, Pages 759-765

  Jung, Klaus ^a   Stephan, Carsten ^a   Elgeti, Ulrike ^a   Lein, Michael ^a   Brux, Brigitte ^a   Kristiansen, Glen ^a   Rudolph, Birgit ^a   Hauptmann, Steffen ^a   Schnorr, Dietmar ^a   Loening, Stefan A ^a   Sinha, Pranav ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Benign prostatic hyperplasia; Diagnostic validity; Molecular forms; Prostate biopsy; Prostate cancer; Prostate specific antigen; Receiver operating characteristic; Screening

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CANCER SCREENING; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; RECEIVER OPERATING CHARACTERISTIC; VALIDATION PROCESS;

EID: 0035452394     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1393     Document Type: Article

References (37)

1. Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer
2. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer
3. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements
4. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: An alternative model
5. PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL
6. A PSA threshold of 4.0 ng/mL for early detection of prostate cancer: The only rational approach for men 50 years old and older
7. Lowering PSA cutoffs to enhance detection of curable prostate cancer
8. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer
9. 1-antichymotrypsin
10. 1-antichymotrypsin as an indicator of prostate cancer
11. 1-protease inhibitor in serum
12. Characterization and immunological determination of the complex between prostate-specific antigen and alpha2-macroglobulin
13. Prostate specific antigen: A decade of discovery - What we have learned and where we are going
14. Diagnostic value of percent free prostate-specific antigen: Retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL
15. Ratio free/total PSA (%f-PSA) in men with total PSA 0.5-3 ng/ml - Improvement for prostate cancer detection?
16. Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer
17. Alpha 1-antichymotrypsin-PSA (ACT-PSA): A useful marker in the differential diagnosis of benign hyperplasia and cancer of the prostate?
18. Novel immunoassay for the measurement of complexed prostate-specific antigen in serum
19. 1-antichymotrypsin
20. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis
21. Factors influencing the ratio of free to total prostate specific antigen in serum
22. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: Which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
23. Software for illustrative presentation of basic clinical characteristics of laboratory tests - GraphROC for Windows
24. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, part I
25. Receiver-operating characteristic as a tool for evaluating the diagnostic performance of total prostate specific antigen and its derivatives - What has to be considered?
26. Prostate cancer detection at low prostate specific antigen
27. Enhancing the specificity of prostate-specific antigen (PSA): An overview of PSA density, velocity and age-specific reference ranges
28. Role of PSA and its indices in determining the need for repeat prostate biopsies
29. Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/mL total PSA
30. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system
31. The appropriate lower limit for the percent free prostate-specific antigen reflex range
32. Adding free to total prostate-specific antigen levels in trials of prostate cancer screening
33. Effect of the ratio of free to total prostate-specific antigen on interassay variability in proficiency test samples
34. Prostate-specific antigen, clinical use and staging: An overview
35. Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4 ng/mL
36. Estimation of prostate cancer probability by logistic regression: Free and total prostate-specific antigen, digital rectal examination, and heredity are significant variables
37. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA